# Phase 1 Study of GSK2315698 in Healthy Japanese Subjects

> **NCT02953808** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 18 (actual)

## Conditions studied

- Amyloidosis

## Interventions

- **DRUG:** Placebo
- **DRUG:** GSK2315698

## Key facts

- **NCT ID:** NCT02953808
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2017-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02953808

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02953808, "Phase 1 Study of GSK2315698 in Healthy Japanese Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02953808. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*